It Is All About The Adoption... More Than a Mantra

David Barone

December 17, 2014

www.bmtadvisors.com

www.bmtCROgroup.com

Boston | Germany | Israel



Medical Device Industry Health Report 2014

- Projected CAGR ~5% through next 10 years
- Top 15 companies control >80% market share
- Leaving >\$60B to all other companies; >\$85B by 2020
- US is still and will remain the most important market
 - Size, innovation, leadership / impact, pricing
 - 12 out of top 20 companies are US; 7 EU based; 1 Japan
- Innovation is still strong; 3,000+ 510(k) / year
- M&A: Stronger than ever
 - Deals value are up, but
 - Deals volume are down
 - Large exits: 50% w/ FDA approval; 25% CE; 25% development







1980's

1990's

2000's





1980's

1990's

2000's



Longer Time-To- Adoption Has Considerable Implications






What Changed During the Last 20 Years?

Resistance to change	Providers are vested in current technologies and practices	Greater competition
Multiple decision makers with conflicting interests	Changing economic incentives	Evidence-based medicine looking for more evidence
Slow acceptance by payers	Incremental features and benefits do not justify change	Politics




While Healthcare Markets Continue to Grow...





MORE CHANGES IN STORE...








Do Outcomes Justify the Cost?




More Experience
Better Results

Payers Required a Change to Managed Care






But Healthcare Spending Continue to Exceed GDP




Season: Authors' calculations haved on Name of Foreness: Andyres data



Cost Drivers










Performance Pays Off





Experts Agree...

Rate reviews cannot fundamentally address the growth of health care costs...



PHOTO: THINKSTOCK

...costs must be addressed through payment reform, delivery system changes, an emphasis on prevention and consumer engagement.

National Association of Insurance Commissioners letter to Congress February 23, 2010



Patient Protection and Affordable Care Act (2010)







10,000+

Number of pages of Obamacare regulations (eight times longer than the Bible).

SOURCE: Competitive Enterprise Institute



U.S. CHAMBER OF COMMERCE




Obamacare Regulations

Many Reforms and New Initiatives

- Value-Based Purchasing (VBP) Program

 reward value and patient outcomes, instead of just volume of services
- Reduced Payments for Hospital Acquired Conditions - Stop paying for certain conditions developed while the patient is hospitalized
- Accountable Care Organizations (ACO) shift from fragmented and inconsistent care to coordinated care and measured performance
- **Payment Reforms -** incentivize Quality, not Volume




Outcomes. Sat

Coe



Service)

Value-based purchasing




Devices pricing will be based on ability to remove costs from the system



Implications to Medical Device Companies



Time To 'Market Acceptance' is Increasing










ADOPTION IT'S THE ECONOMY STUPID!





We Have a New Landscape

- Volume based incentives
- Individual providers
- Fee-for-service
- Payers assume financial risk
- Site of service hospital
- **Documenting care**
- Brand defines quality
- Device selected by physician \rightarrow

- Value based / outcomes \rightarrow
- **Providers consolidation** \rightarrow
- **Bundled care** \rightarrow
- **Payers & providers** \rightarrow
 - \rightarrow Least expensive
 - **Coordination of care** \rightarrow
 - Quality defines brand \rightarrow
- System decisions



What Do We Need To Learn Early On?

Who is the first market?

- Who will be our initial target?
- Check with all the right people, not only MD's

Benefits

- Improved patient care and/or delivery of care
- How does our solution compare with the current standard-of-care?

Standard of care

- Guidelines
- What actually happens in the field, why?

Regulatory

 Need to understand the strategy at the very outset of product development

Reimbursement

- Cost and effectiveness of existing alternatives
- Availability and level of payments for similar devices
- Codes and payments for professional and institutional services

Clinical studies

 Roadmap beyond regulatory approval



How To Spend Early Funds?



- Develop a roadmap
- Reduce the primary risks

Common mistakes:

- No clear understanding / rationale of first target market, or picking the wrong market
- Using funds to refine prototype designs (beyond proof of concept)
- Under investing in IP
- Staffing up prematurely instead of relying on external experts (typ. Offering broader experience at lower cost than internal hires)
- Rushing to market before addressing market risks



Transitioning To Sales

- The old good days (1) develop, (2) sell are over
- Make sure you have a scalable model before hiring sales force, signing national distributors or booking the 30'x30' booth
- Without the proper evidence your ability to sell and scale are slim
- First 2 years:
 - Understand your clinical and economic value
 - Is the product ready for prime time
 - What support services are needed?
- Track meaningful metrics #1: Repeat purchases
- Don't jump to the water naked (w/o the skills and funds)



A Few Myths

- A great product will sell itself... sorry, it will not...
- We are not good at marketing, so once we get the 510k we will sign the right distributor... and you really expect them to do <u>your</u> work?...



• We don't have money, we need to be creative...cutting corners and still expect to make it?...



More Myths...



We will do the studies needed to get FDA / CE approvals and the early customers will do the rest... we can certainly hope this will be the case, but 'hope' is generally not a good plan...

We do not need Business Plan... we really do not know what is our plan...

Once we get money we will do the right staff...unfortunately investors want you to do the right staff before they give you the money ...





